Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Lymphangioleiomyomatosis 1Fallopian Tube Neoplasms 1Breast Neoplasms 1

Interventions

Sirolimus 9Everolimus 3Imatinib Mesylate 2temsirolimus 1saracatinib 1nintedanib 1carbon-11 acetate 1Valproic Acid 1Urination 1Sugars 1Simvastatin 1Resveratrol 1Respiratory Function Tests 1Phlebotomy 1Loratadine 1Letrozole 1Immunoglobulin G 1Hydroxychloroquine 1Glutamine 1Genetic Testing 1Doxycycline 1Disulfides 1Cetuximab 1Celecoxib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphangioleiomyomatosis × saracatinib × Clear all
NCT02116712 2016-11-30

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Baylor College of Medicine

Phase 1 Completed
9 enrolled

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡